Fc Receptors Are Required in Passive and Active Immunity to Melanoma

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1998 Jan 22

PMID 9435247

Citations 110

Authors

R Clynes

Y Takechi

Y Moroi

A Houghton

J V Ravetch

Affiliations

Soon will be listed here.

Abstract

Effective tumor immunity requires recognition of tumor cells coupled with the activation of host effector responses. Fc receptor (FcR) gamma-/- mice, which lack the activating Fc gamma R types I and III, did not demonstrate protective tumor immunity in models of passive and active immunization against a relevant tumor differentiation antigen, the brown locus protein gp75. In wild-type mice, passive immunization with mAb against gp75 or active immunization against gp75 prevented the development of lung metastases. This protective response was completely abolished in FcR gamma-deficient mice. Immune responses were intact in gamma-/- mice because IgG titers against gp75 develop normally in gamma-/- mice immunized with gp75. However, uncoupling of the Fc gamma R effector pathway from antibody recognition of tumor antigens resulted in a loss of protection against tumor challenge. These data demonstrate an unexpected and critical role for FcRs in mediating tumor cytotoxicity in vivo and suggest that enhancement of Fc gamma R-mediated antibody-dependent cellular cytotoxicity by inflammatory cells is a key step in the development of effective tumor immunotherapeutics.

Citing Articles

Cancer biotherapy: review and prospect.

Liu Q, Ma H Clin Exp Med. 2024; 24(1):114.

PMID: 38801637 PMC: 11130057. DOI: 10.1007/s10238-024-01376-2.

BAG3 as a novel prognostic biomarker in kidney renal clear cell carcinoma correlating with immune infiltrates.

Gong B, Huang Y, Wang Z, Wan B, Zeng Y, Lv C Eur J Med Res. 2024; 29(1):93.

PMID: 38297320 PMC: 10832118. DOI: 10.1186/s40001-024-01687-w.

The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.

Osorio J, Smith P, Knorr D, Ravetch J Cancer Cell. 2023; 41(12):2051-2065.e6.

PMID: 37977147 PMC: 10842210. DOI: 10.1016/j.ccell.2023.10.007.

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions.

Osorio J, Smith P, Knorr D, Ravetch J bioRxiv. 2023; .

PMID: 37455857 PMC: 10347539. DOI: 10.1101/2023.06.29.547082.

New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus.

Diethelm-Varela B, Soto J, Riedel C, Bueno S, Kalergis A Infect Drug Resist. 2023; 16:2061-2074.

PMID: 37063935 PMC: 10094422. DOI: 10.2147/IDR.S379660.

References

Takechi Y, Hara I, Naftzger C, Xu Y, Houghton A . A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res. 1996; 2(11):1837-42. View

Vora K, Ravetch J, Manser T . Amplified follicular immune complex deposition in mice lacking the Fc receptor gamma-chain does not alter maturation of the B cell response. J Immunol. 1997; 159(5):2116-24. View

Rosenberg S, White D . Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996; 19(1):81-4. View

Takai T, Li M, Sylvestre D, Clynes R, Ravetch J . FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994; 76(3):519-29. DOI: 10.1016/0092-8674(94)90115-5. View

Hann S, Koo S, Kim J, Park Y . Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. J Dermatol. 1996; 23(2):100-3. View

Clynes R, Ravetch J . Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995; 3(1):21-6. DOI: 10.1016/1074-7613(95)90155-8. View

Sylvestre D, Ravetch J . Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 1994; 265(5175):1095-8. DOI: 10.1126/science.8066448. View

Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M . Melanoma-associated hypopigmentation: where are the antibodies?. Am J Clin Oncol. 1996; 19(6):613-8. DOI: 10.1097/00000421-199612000-00017. View

Jaffee E, Pardoll D . Murine tumor antigens: is it worth the search?. Curr Opin Immunol. 1996; 8(5):622-7. DOI: 10.1016/s0952-7915(96)80077-x. View

10.

Wang R, Robbins P, Kawakami Y, Kang X, Rosenberg S . Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995; 181(2):799-804. PMC: 2191858. DOI: 10.1084/jem.181.2.799. View

11.

Ravetch J . Fc receptors. Curr Opin Immunol. 1997; 9(1):121-5. DOI: 10.1016/s0952-7915(97)80168-9. View

12.

Houghton A . Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994; 180(1):1-4. PMC: 2191545. DOI: 10.1084/jem.180.1.1. View

13.

Hara I, Takechi Y, Houghton A . Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995; 182(5):1609-14. PMC: 2192219. DOI: 10.1084/jem.182.5.1609. View

14.

Livingston P, Wong G, Adluri S, Tao Y, Padavan M, Parente R . Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994; 12(5):1036-44. DOI: 10.1200/JCO.1994.12.5.1036. View

15.

Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton A . Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A. 1996; 93(25):14809-14. PMC: 26218. DOI: 10.1073/pnas.93.25.14809. View

16.

Fishman P, Merimski O, Baharav E, Shoenfeld Y . Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer. 1997; 79(8):1461-4. DOI: 10.1002/(sici)1097-0142(19970415)79:8<1461::aid-cncr3>3.0.co;2-e. View

17.

Vijayasaradhi S, Bouchard B, Houghton A . The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med. 1990; 171(4):1375-80. PMC: 2187848. DOI: 10.1084/jem.171.4.1375. View

18.

Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Fishman P . Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother. 1996; 42(5):297-302. PMC: 11037609. DOI: 10.1007/s002620050286. View

19.

Suzuki Y, Shirato I, Okumura K, Ravetch J, Takai T, Tomino Y . Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 1998; 54(4):1166-74. DOI: 10.1046/j.1523-1755.1998.00108.x. View

20.

Diamond B, Yelton D . A new Fc receptor on mouse macrophages binding IgG3. J Exp Med. 1981; 153(3):514-9. PMC: 2186114. DOI: 10.1084/jem.153.3.514. View